117 related articles for article (PubMed ID: 7922132)
1. Theoretical quantitative structure-activity relationship analysis on three dimensional models of ligand-m1 muscarinic receptor complexes.
Fanelli F; Menziani MC; Carotti A; De Benedetti PG
Bioorg Med Chem; 1994 Mar; 2(3):195-211. PubMed ID: 7922132
[TBL] [Abstract][Full Text] [Related]
2. Modelling of the binding site of the human m1 muscarinic receptor: experimental validation and refinement.
Bourdon H; Trumpp-Kallmeyer S; Schreuder H; Hoflack J; Hibert M; Wermuth CG
J Comput Aided Mol Des; 1997 Jul; 11(4):317-32. PubMed ID: 9334899
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations of m3-muscarinic receptor activation and QSAR analysis.
Fanelli F; Menziani MC; De Benedetti PG
Bioorg Med Chem; 1995 Nov; 3(11):1465-77. PubMed ID: 8634826
[TBL] [Abstract][Full Text] [Related]
4. Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding.
Vistoli G; Pedretti A; Dei S; Scapecchi S; Marconi C; Romanelli MN
Bioorg Med Chem; 2008 Mar; 16(6):3049-58. PubMed ID: 18182302
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
Messer WS; Abuh YF; Liu Y; Periyasamy S; Ngur DO; Edgar MA; El-Assadi AA; Sbeih S; Dunbar PG; Roknich S; Rho T; Fang Z; Ojo B; Zhang H; Huzl JJ; Nagy PI
J Med Chem; 1997 Apr; 40(8):1230-46. PubMed ID: 9111297
[TBL] [Abstract][Full Text] [Related]
6. Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site.
Heitz F; Holzwarth JA; Gies JP; Pruss RM; Trumpp-Kallmeyer S; Hibert MF; Guenet C
Eur J Pharmacol; 1999 Sep; 380(2-3):183-95. PubMed ID: 10513578
[TBL] [Abstract][Full Text] [Related]
7. Identification of a ligand-dependent switch within a muscarinic receptor.
Spalding TA; Burstein ES; Henderson SC; Ducote KR; Brann MR
J Biol Chem; 1998 Aug; 273(34):21563-8. PubMed ID: 9705286
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling of the interaction of diagnostic radiopharmaceuticals with receptor proteins: m2 antagonist binding to the muscarinic m2 subtype receptor.
Kapp OH; Siemion J; Eckelman WC; Cohen VI; Reba RC
Recept Signal Transduct; 1997; 7(3):177-201. PubMed ID: 9440504
[TBL] [Abstract][Full Text] [Related]
9. The predicted 3D structures of the human M1 muscarinic acetylcholine receptor with agonist or antagonist bound.
Peng JY; Vaidehi N; Hall SE; Goddard WA
ChemMedChem; 2006 Aug; 1(8):878-90. PubMed ID: 16902941
[TBL] [Abstract][Full Text] [Related]
10. Use of an in situ disulfide cross-linking strategy to map proximities between amino acid residues in transmembrane domains I and VII of the M3 muscarinic acetylcholine receptor.
Hamdan FF; Ward SD; Siddiqui NA; Bloodworth LM; Wess J
Biochemistry; 2002 Jun; 41(24):7647-58. PubMed ID: 12056896
[TBL] [Abstract][Full Text] [Related]
11. Binding-site modeling of the muscarinic m1 receptor: a combination of homology-based and indirect approaches.
Nordvall G; Hacksell U
J Med Chem; 1993 Apr; 36(8):967-76. PubMed ID: 8478909
[TBL] [Abstract][Full Text] [Related]
12. Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives.
Dei S; Angeli P; Bellucci C; Buccioni M; Gualtieri F; Marucci G; Manetti D; Matucci R; Romanelli MN; Scapecchi S; Teodori E
Biochem Pharmacol; 2005 Jun; 69(11):1637-45. PubMed ID: 15896343
[TBL] [Abstract][Full Text] [Related]
13. Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling.
Wess J; Blin N; Mutschler E; Blüml K
Life Sci; 1995; 56(11-12):915-22. PubMed ID: 10188793
[TBL] [Abstract][Full Text] [Related]
14. Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function.
Ward SD; Curtis CA; Hulme EC
Mol Pharmacol; 1999 Nov; 56(5):1031-41. PubMed ID: 10531410
[TBL] [Abstract][Full Text] [Related]
15. Thienocycloheptapyridazines as new muscarinic agents.
Barlocco D; Cignarella G; Fanelli F; Vitalis B; Matyus P; De Benedetti PG
Drug Des Discov; 1997 Apr; 14(4):273-90. PubMed ID: 9197979
[TBL] [Abstract][Full Text] [Related]
16. Site-directed mutagenesis of m1-toxin1: two amino acids responsible for stable toxin binding to M(1) muscarinic receptors.
Krajewski JL; Dickerson IM; Potter LT
Mol Pharmacol; 2001 Oct; 60(4):725-31. PubMed ID: 11562434
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain.
Huang XP; Williams FE; Peseckis SM; Messer WS
J Pharmacol Exp Ther; 1998 Sep; 286(3):1129-39. PubMed ID: 9732369
[TBL] [Abstract][Full Text] [Related]
18. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: the significance of Tyr403 in the binding of agonists and functional coupling.
Vogel WK; Sheehan DM; Schimerlik MI
Mol Pharmacol; 1997 Dec; 52(6):1087-94. PubMed ID: 9415719
[TBL] [Abstract][Full Text] [Related]
19. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
Jakubík J; Bacáková L; El-Fakahany EE; Tucek S
Mol Pharmacol; 1997 Jul; 52(1):172-9. PubMed ID: 9224827
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease.
Clader JW; Wang Y
Curr Pharm Des; 2005; 11(26):3353-61. PubMed ID: 16250841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
